Xagenic Looks To Launch Point-of-Care Molecular Dx Platform Targeting Infectious Disease
This article was originally published in The Gray Sheet
Executive Summary
The start-up has created the Xagenic X1 platform to run molecular diagnostic tests in a physician's office in about 20 minutes instead of sending samples out to a lab. The company plans to address chlamydia and gonorrhea first, and to establish a presence in the sexually transmitted infections, women's health, and urgent and primary care markets.
You may also be interested in...
Xagenic Inc.
Xagenic Inc.’s Amplified Redox Assay (AuRA) POC system utilizes chip-based arrays of microelectrodes to test samples for the presence of telltale nucleic acid strands. Because it is chip-based, it should be simple to run multiple tests on a single chip, and no sample extraction or preparation is needed to run the test.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.